Abstract:e16180 Background: Hepatocellular carcinoma (HCC) is an aggressive malignancy with limited treatment options. The emerging field of tumor immunotherapy, primarily focusing on CD8+ T cells and the tumor microenvironment (TME), has garnered substantial attention. CD4+ T cells, on the other hand, play a crucial role in maintaining immune equilibrium and orchestrating immune responses through interactions with various cell types. As crucial participants and coordinators in innate and adaptive immune responses, the role of CD4+ T cells in tumor development remain further exploration. Conventional dendritic cells (cDCs) are thought to perform antigen presentation to prime CD4+ T cells or CD8+ T cells. However, the reverse regulatory impact of CD4+ T cells on cDCs remains poorly understood. Methods: Initially, we examined the role of CD4+ T cell subsets in HCC development using TCGA database. Subsequently, we established Cd4-Cre Bcl9fl/fl Bcl9lfl/fl mice to explore the impact of T cell-specific Bcl9/Bcl9l deficiency on HCC development. We further investigate the impact of Bcl9/Bcl9l deficiency in CD4+ T cells on the therapeutic efficacy of mouse CAR-T treatment. Moreover, using single-cell RNA sequencing (scRNA-seq) databases from Bcl9/Bcl9l KO tumor-bearing mice and HCC patients, we investigated the regulatory role of CD4+ T cells on the function of cDCs. Finally, we validated the mechanism by which CD4+ T cells regulate cDCs function in a mouse HCC model and explored their influence on tumor-specific CD8+ T cells response. Results: We found elevated Th1 cell infiltration in various cancers including liver hepatocellular carcinoma (LIHC). High Th1 infiltration is associated with a favorable prognosis in LIHC, but there is a significant negative correlation between the expression of B-cell lymphoma 9/B-cell lymphoma 9-like (BCL9/BCL9L) and the infiltration of Th1 cells. We found that blocking T cell-intrinsic BCL9/BCL9L increased frequencies of Th1 cells, thereby suppressing HCC tumor growth. The enrichment of Th1 cells inversely regulates innate immune response to augment cDCs activation. BCL9/BCL9L inhibition amplifies CD4+ T cell and cDCs crosstalk and promotes cDCs antigen presentation. The reinforced cross-presentation of tumor antigens by cDCs promotes activation and proliferation of CD8+ T cells. Moreover, genetic editing of BCL9/BCL9L in CD4+ T cells can enhance the anti-tumor immunity by promoting CAR-T cell toxicity. Conclusions: Thus, BCL9/BCL9L inhibition orchestrate an adaptive immune to innate immune circuit wherein Th1 cells triggers cDCs antigen presentation in turn activate tumor-specific CD8+ T cells response to promote cancer immunity.

Expression of B7-1 and B7-2 Mediated by Adenovirus Enhanced T Cell Anti-Hepatoma Immunity

Triple Expression of B7-1, B7-2 and 4-1BBL Enhanced Antitumor Immune Response Against Mouse H22 Hepatocellular Carcinoma

Functional Expression of B7H1 on Pancreatic Carcinoma Panc-1 Cells

Immunotherapy of Hepatocellular Carcinoma: Recent Progress and New Strategy.

Immunotherapy for Hepatoma Using A Dual-Function Vector with Both Immunostimulatory and Pim-3-Silencing Effects

Prevention of Hepatocellular Carcinoma in Mice by IL-2 and B7-1 Genes Co-Transfected Liver Cancer Cell Vaccines

[Immunoprotective Effect of IL-2 and B7-1 Gene Co-Transfected Liver Cancer Vaccines on Hepatocarcinogenesis in Mice].

Expression of co-stimulator 4-1BB molecule in hepatocellular carcinoma and adjacent non-tumor liver tissue, and its possible role in tumor immunity.

Potent Antitumor Activity Generated by a Novel Tumor Specific Cytotoxic T Cell.

Recombinant Adenovirus Expressing a Soluble Fusion Protein PD-1/CD137L Subverts the Suppression of CD8+ T Cells in HCC.

Improvement of the Cytotoxic T Lymphocyte Response Against Hepatocellular Carcinoma by Transduction of Cancer Cells with an Adeno-Associated Virus Carrying the Interferon-Γ Gene.

Key oncogenic signaling pathways affecting tumor-infiltrating lymphocytes infiltration in hepatocellular carcinoma: basic principles and recent advances

Activation of Endogenous CD4 T Cells Stimulates Favorable Immunologic Changes in the Tumor Milieu and Enhances the Antitumor Effect of Lentivector Immunization (48.15)

Inoculation with IL-2 and B7-1 Co-Transfected G422 Murine Glioblastoma Cells Resulting in Enhanced Antitumor Immunity in Vivo

Induction of Tumor Immunity and Cytotoxic T Lymphocyte Responses Using Dendritic Cells Transduced by Adenoviral Vectors Encoding HBsAg: Comparison to Protein Immunization

Immune checkpoint of B7-H3 in cancer: from immunology to clinical immunotherapy

Transfection of B7-1 cDNA empowers antigen presentation of blood malignant cells for activation of anti-tumor T cells.

Effect of BCL9/BCL9L Inhibition–derived Th1 Cells on Dendritic Cells–mediated Antigen Presentation in Hepatocellular Carcinoma and on the Efficacy of CAR-T Immunotherapy.

B7-H3 in tumors: friend or foe for tumor immunity?

Targeted Hsp70 Expression Combined with Cik-Activated Immune Reconstruction Synergistically Exerts Antitumor Efficacy in Patient-Derived Hepatocellular Carcinoma Xenograft Mouse Models

Strengthening of antitumor effects in breast cancer from a novel B7-H4- and CD3-targeting bispecific antibody by an oncolytic virus